Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials

Fig. 4

Efficacy for patients who did not experience radiographic progression in the pcJIA trial. a Efficacy response for patients who did not experience adapted SH progression based on SDD at week 52 compared with response rates for all patients in the continuous TCZ population. b Efficacy response for patients who did not experience adapted SH progression based on SDD at week 104 compared with response rates for all patients in the continuous TCZ population. JIA ACR, juvenile idiopathic arthritis American College of Rheumatology response; pcJIA, polyarticular-course juvenile idiopathic arthritis; SDD, smallest detectable difference; SH, Sharp–van der Heijde; TCZ, tocilizumab

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us